| ¿µ¹® | rheumatoid factor | ÇÑ±Û | ·ù¸¶Æ¼½º ÀÎÀÚ |
|---|---|---|---|
| ¼³¸í | IgGÀÇ FcºÎÀ§¿¡ ÀÖ´Â Ç׿ø°áÁ¤ÀÎÀÚ¿¡ ´ëÇÑ Ç×ü·Î¼ ÀüÇüÀûÀÎ ¶Ç´Â È®½ÇÇÑ ·ù¸¶Æ¼½º°üÀý¿°(rheumatoid arthritis) ȯÀÚÀÇ 80%¿¡¼ ¹ß°ßµÈ´Ù. ·ù¸¶Æ¼½º ÀÎÀÚ´Â IgM, IgG, IgAÁß Çϳª°¡ µÉ ¼ö ÀÖÀ¸³ª ÁÖ·Î IgMÀÌ´Ù. ¼Ò¾Æ·ù¸¶Æ¼½º°üÀý¿°(juvenile rheumatoid arthritis: ¼Ò¾Æ±â¿¡ ¹ß»ýÇÏ´Â ·ù¸¶Æ¼½º°üÀý¿°)À» ºñ·ÔÇÑ, ´Ù¸¥ °áÇÕÁ¶Á÷º´À̳ª °¨¿°º´¿¡µµ ³ªÅ¸³¯ ¼ö ÀÖ´Ù |
||
| ¿µ¹® | growth factor | ÇÑ±Û | ¼ºÀåÀÎÀÚ |
|---|---|---|---|
| ¼³¸í | ¼¼Æ÷ÀÇ ºÐÈ ¹× ¼ºÀå¿¡ °ü¿©ÇÏ´Â ´Ü¹éÁú. ¼ºÀåÀÎÀÚ´Â Á¤»ó ¼¼Æ÷Áֱ⿡ ÇʼöÀûÀ̱⠶§¹®¿¡ µ¿¹°ÀÇ »ý¸í¿¡ Áß´ëÇÑ ¿ä¼Ò°¡ µÈ´Ù. ¹«¾ùº¸´Ùµµ ¼ºÀåÀÎÀڴ žÆÀÇ ¹ßÀ°À» Á¶Á¤Çϰí Á¶Á÷ÀÇ À¯Áö ¹× º¸¼ö¿¡ Áß´ëÇÑ ¿ªÇÒÀ» Çϸç, Ç÷±¸ÀÇ »ý¼ºÀ» ÀÚ±ØÇÑ´Ù. ¶ÇÇÑ ¾ÏÀÇ ÁøÇà°úÁ¤¿¡µµ °ü¿©ÇÑ´Ù. |
||
| ¿µ¹® | risk factor | ÇÑ±Û | À§ÇèÀÎÀÚ |
|---|---|---|---|
| ¼³¸í | ±¹Á¦¹æ»ç¼±¹æÈ£À§¿øÈ¸(ICRP)°¡ 1977³â ±Ç°í¿¡¼ ¹æ»ç¼±¹æÈ£ÀÇ ¸ñÀûÀ¸·Î äÅÃÇÑ Áö¼ö·Î, ´ÜÀ§¼±·®(1 Sv)´ç È®·üÀû ¿µÇâÀÇ ¹ß»ýÈ®·üÀ» ÃßÁ¤ÇÏ¿© ³ªÅ¸³½ °ÍÀÌ´Ù. »ý½Ä¼± ¼±·®¿¡ ´ëÇÑ À¯ÀüÀû¿µÇâÀÇ ¹ß»ý·ü(4¡¿10£3/Sv)À̳ª Àû»ö°ñ¼ö¼±·®¿¡ ´ëÇÑ ¹éÇ÷º´ ¹ß»ý·ü(2¡¿10£3/Sv)µî ¿Ü¿¡ »À, ÇãÆÄ, °©»ó»ù, Á¥»ù, ±âŸ Á¶Á÷ÀÇ À§ÇèÁö¼ö¸¦ ÃøÁ¤ÇÏ¿©, È®·üÀû ¿µÇâÀÇ Àü½Å¿¡ ÀÖ¾î¼ Ä¡»çÀ§ÇèÁö¼öÀÇ Çհ踦 16.5¡¿10£3/Sv·Î ÇÏ¿´´Ù. ±×ÈÄ ICRP´Â 1990³â ±Ç°í¿¡¼ ´ë»óÀÌ µÇ´Â Á¶Á÷°ú Àå±â¸¦ Ãß°¡Çϰí, ¼öÄ¡ °³Á¤À» ÇÏ¸é¼ ¸íεµ °¢¸ñÀûÈ®·üÁö¼ö¶ó°íÇÏ¿´´Ù. ÀÌ ±Ç°í¿¡ ÀÇÇϸé, Ä¡»çÀû È®·üÀû ¿µÇâÀÇ È®·üÁö¼öÀÇ ÇÕ°è´Â, ÀϹÝÀο¡ ÀÖ¾î 60.0¡¿10£3/SvÀÌ´Ù. |
||
| ¿µ¹® | necrosis | ÇÑ±Û | ±«»ç |
|---|---|---|---|
| ¼³¸í | ¼¼Æ÷°¡ Á×´Â °ÍÀ» ¸»ÇÑ´Ù. ¿øÀÎÀº ¾î¶² ¿Ü»óÀÏ ¼öµµ ÀÖ°í, ȤÀº µ¿¸ÆÀÌ Á¼¾ÆÁ®¼ Çǰ¡ ÅëÇÏÁö ¾Ê¾Æ Á×°Ô µÇ´Â °ÍÀÏ ¼öµµ ÀÖ´Ù. ¾î¶² °æ¿ìÀ̵ç, ±«»çµÈ Á¶Á÷ÀÌ Ã¼³»¿¡ ÀÖÀ¸¸é, °á±¹Àº ¿©·¯ ÇÕº´ÁõÀ» ºÒ·¯ ÀÏÀ¸Å°¹Ç·Î Á¦°ÅµÇ¾î¾ß ÇÑ´Ù. ±«Àú±«»ç: gangrenous necrosis ±«Àú±«»ç¶ó´Â ¿ë¾î´Â º¸Åë ±«»ç¶ó´Â °Í°ú Å©°Ô ´Ù¸¥ °ÍÀº ¾øÀ¸³ª ÀÓ»ó, ƯÈ÷ ¿Ü°ú¿¡¼ ÈçÈ÷ ¾²°í ÀÖ´Â ¸»ÀÌ´Ù. ÀÌ´Â ÆÈ´Ù¸®, ƯÈ÷ ´Ù¸®¿¡¼ ¸¹ÀÌ »ý±â´Âµ¥ Ç÷¾×°ø±ÞÀÌ ¼Ò½ÇµÇ°í ±× ÈÄ¿¡ ¼¼±Õ°¨¿°À» ¹Þ¾Æ¼ »ý±â´Â º´ÅÍÀÌ´Ù. ¸¸¾à Ç÷·ù°ø±ÞÀÇ Â÷´Ü¿¡ ÀÇÇÑ Á¶Á÷ÀÇ Á×À½ÀÌ ÁÖº´º¯À̰í ÀÌÂ÷Àû ¼¼±ÕÀÇ °¨¿°ÀÌ Àû°í, ÀÖ´õ¶óµµ ¾ÆÁÖ ¹Ì¾àÇØ¼ º´ÅͰ¡ ¸¶¸£°í ¾×ü¼ººÐÀÌ ÀûÀ» °æ¿ì¿¡ À̰ÍÀ» °Ç¼º±«Àú(dry gangrene)À̶ó°í Çϰí, ¼¼±ÕÀÇ °¨¿°ÀÌ ¾ÆÁÖ ¸¹¾Æ¼ Á×Àº Á¶Á÷ÀÌ ºÐÇØ°¡ µÇ¾î¼ ¾×ü¼ººÐÀÌ ±«ÀúÀÇ Á¶Á÷¿¡ ¸¹ÀÌ ÀÖ¾î¼ º¸±â¿¡ ½ÀÇØ º¸À̸é À̰ÍÀ» ½À¼º±«Àú(wet gangrene)À̶ó°í ÇÑ´Ù. |
||
| ¿µ¹® | fibrinoid necrosis | ÇÑ±Û | ¼¶À¯¼Ò¼º±«»ç |
|---|---|---|---|
| ¼³¸í | ÃʱâÀÇ ·ù¸¶Æ¼½º ȤÀº ¾Ç¼ºÁ¾¾ç µî¿¡¼ º¼ ¼ö ÀÖ´Â Ç÷°ü-°áÇÕÁ¶Á÷ÀÇ Æ¯À¯ÇÑ º¯È·Î Ç÷°üº®À̳ª ÁÖÀ§ÀÇ °áÇÕÁ¶Á÷ÀÌ ¼¶À¯¼Ò¸ð¾çÀ¸·Î ±ÕÁúÇÑ ¹°Áú·Î µÇ°í, È£»ê¼ºÀ¸·Î ¿°»öµÈ´Ù. À̰ÍÀº ¼¶À¯¼Ò¿Í °ÅÀÇ ¶È°°Àº ¿°»ö¼ºÀ» ³ªÅ¸³»±â ¶§¹®¿¡ ¿°Áõ¿¡¼ Ç÷°üÀ¸·ÎºÎÅÍ ¼¶À¯¼Ò ¶Ç´Â ¼¶À¯¼Ò¸ð¾çÀÇ ¹°ÁúÀÌ »ïÃâÇÏ¿© °áÇÕÁ¶Á÷ ¼¶À¯°£¿¡ Ä§ÂøÇÏ¿© ±¸Á¶°¡ ºÒ¸í·áÇÑ °ÍÀ¸·Î »ý°¢µÇ¾úÀ¸³ª, ÃÖ±Ù Á¶Á÷ÈÇÐ, ÀüÀÚÇö¹Ì°æ µî¿¡ ÀÇÇÏ¿© °áÇÕ¼¶À¯ÀÚü¿¡µµ º¯È°¡ ÀÖ´Â °ÍÀ¸·Î ¸é¿ª±Û·ÎºÒ¸°ÀÇ Ä§Âøµµ Áõ¸íµÇ°í ÀÖ´Ù. |
||
| CF | calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ... |
|---|---|
| EF | ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e... |
| PF | pair feeding; peak flow; perfusion fluid; pericardial fluid; periosteal fibroblast; peritoneal fluid... |
| TIF | tumor-inducing factor; tumor-inhibiting factor |
| TNF | Tumor Necrosis Factor; Á¾¾ç ±«»ç ÀÎÀÚ |
| TNF | Anti-tumor necrosis factor |
|---|---|
| anti-TNF alpha | Anti-tumor necrosis factor alpha |
| TNF | Cachectin/tumor necrosis factor |
| enTNF | Endogenous tumor necrosis factor |
| hTNF-alpha | Human Tumor Necrosis Factor-alpha |
IGF-II : insulin like growth factor-IIÀÇ ¾àÀÚ. ¸¹Àº Àå±â¿Í Á¶Á÷¿¡ ÀÛ¿ëÇÏ¿© ´Ü¹é ÇÕ¼º°ú DNA, RNAÀÇ ÇÕ¼ºÀ» Áõ°¡½ÃÄÑ ¼¼Æ÷ÀÇ ¼ö¿Í ¾çÀ» Áõ°¡
| tumor necrosis factor | <cytokine> Originally described as a tumour inhibiting factor in the blood of animals exposed to bacterial lipopolysaccharide or Bacille Calmette-Guerin. Preferentially kills tumour cells in vivo and in vitro, causes necrosis of certain transplanted tumours in mice and inhibits experimental metastases. Human Tumour Necrosis factor alpha is a protein of 157 amino acids and has a wide range of pro inflammatory actions. Usually considered a cytokine. Synonym: cachectin. Acronym: TNF (13 Nov 1997) |
|---|
| tumor | 1. <oncology> An abnormal mass of tissue that results from excessive cell division that is uncontrolled and progressive, also called a neoplasm. Tumours perform no useful body function. They may be either benign (not cancerous) or malignant. 2. Swelling, one of the cardinal signs of inflammations, morbid enlargement. Origin: L. Tumere = to swell (12 May 1997) |
|---|---|
| tumor marker | <investigation, oncology> A substance in the body that usually indicates the presence of cancer. These markers are usually specific to certain types of cancer and are usually found in the blood or other tissue samples. Examples are alphafetoprotein (AFP), human chorionic gonadotropin, and lactate dehydrogenase (LDH). They may be indicators of tumour stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids. (18 Jul 2002) |
| p60 tumour necrosis factor receptor-associated kinase | <enzyme> Interacts with and causes phosphorylation of the cytoplasmic domain of the tnf receptor Registry number: EC 2.7.10.- Synonym: p60 tnf receptor-associated kinase, p60-trak (26 Jun 1999) |
| receptors, tumour necrosis factor | Cell surface receptors that bind tumour necrosis factor and trigger changes which influence the behaviour of cells. The two recognised tumour necrosis factor receptors are designated alpha and beta receptors. Both receptors bind both alpha and beta tumour necrosis factors with high affinity, and both are members of the nerve growth factor receptor family. (12 Dec 1998) |
| tumour necrosis factor | <cytokine> Originally described as a tumour inhibiting factor in the blood of animals exposed to bacterial lipopolysaccharide or Bacille Calmette-Guerin. Preferentially kills tumour cells in vivo and in vitro, causes necrosis of certain transplanted tumours in mice and inhibits experimental metastases. Human Tumour Necrosis factor alpha is a protein of 157 amino acids and has a wide range of pro inflammatory actions. Usually considered a cytokine. Synonym: cachectin. Acronym: TNF (13 Nov 1997) |
| tumour necrosis factor-beta | <cytokine> A cytolytic factor that is produced by CD4 and CD8 T-cells after their exposure to an antigen. (05 Mar 2000) |
| acute tubular necrosis | <nephrology> A kidney disorder that results in damage to the renal tubule cells leading to acute renal failure. Acute tubular necrosis can result from any condition which deprives the kidney of oxygen (ischaemia). Acute tubular necrosis may occur as a complication of shock, trauma or sepsis. Conditions such as diabetes or liver disease can predispose people to the development of acute tubular necrosis. Certain medications (for example aminoglycosides, amphotericin B, cyclosporine) are known to cause acute tubular necrosis as a toxic side effect. Radiopaque contrast dyes, used in some radiologic procedures, may also result in acute tubular necrosis as a rare complication from contrast dye use. Acronym: ATN (13 Nov 1997) |
| aseptic necrosis | <orthopaedics, pathology> Condition in which poor blood supply to an area of bone leads to bone death. Also called avascular necrosis and osteonecrosis. (12 Dec 1998) |
| avascular necrosis | <radiology> Aetiology (PLASTIC RAGS): P pancreatitis, L lupus, A alcohol, S steroids, T trauma, I idiopathic, infection, C caisson disease, collagen vascular disease, R radiation, rheumatoid arthritis, A amyloid, G Gaucher disease, S sickle cell disease findings: sclerosis, crescent sign, collapse (e.g., of femoral head) see also: staging (12 Dec 1998) |
| avascular necrosis staging | <radiology> Stage CT/X-ray bone scan I - cold/hot spot II sclerotic focus with osteopenic ring III crescent sign (subchondral lucency) IV articular collapse flattening of femoral head sensitivity 86% 78% specificity 79% 75% see also: avascular necrosis (AVN) (12 Dec 1998) |
| bridging hepatic necrosis | Area of liver necrosis which bridges adjacent portal areas and central veins; subsequent post-necrotic collapse and fibrosis is likely to result in cirrhosis. (05 Mar 2000) |
| papillary necrosis | <radiology> Mnemonic: POST CARD, P pyelonephritis, O obstruction, S sickle cell disease, T TB, C cirrhosis (EtOH), A analgesics (phenacetin and aspirin), R renal vein thrombosis, D diabetes (12 Dec 1998) |
| caseous necrosis | Caseation necrosis, necrosis characteristic of certain inflammations (e.g., tuberculosis, histoplasmosis), which represents necrosis with loss of separate structures of the various cellular and histologic elements; affected tissue manifests the friable, crumbly consistency and dull, opaque quality observed in cheese. Synonym: caseous degeneration. (05 Mar 2000) |
| globus pallidus necrosis | <radiology> Carbon monoxide poisoning, barbiturate intoxication, cyanide poisoning, hydrogen sulfide poisoning, hypoglycaemia, hypoxia, hypotension, Leigh disease, Wilson disease CT: bilateral, symmetric low density in globus pallidus Cf: methanol intoxication leading to putamenal haemorrhagic necrosis (changes seen more laterally) (12 Dec 1998) |
| renal papillary necrosis | <nephrology> Necrosis of renal papillae, occurring in acute pyelonephritis, especially in diabetics, or in analgesic nephropathy; renal failure may result. Synonym: necrotizing papillitis. (05 Mar 2000) |
Synonyms : Decoy Receptor for FAS Ligands, Decoy Receptor for TRAIL Ligands, Decoy Receptor, Tumor Necrosis Factor, Tumor Necrosis Factor Decoy Receptor, FAS Receptors, Decoy, Receptors, Decoy FAS, Receptors, Decoy TRAIL, TRAIL Receptors, Decoy
Synonyms : A Proliferation Inducing Ligand Protein, APRIL Protein, TALL-2 Protein, TNF- and APOL-Related Leukocyte Expressed Ligand 2 Protein, TALL 2 Protein, TNF and APOL Related Leukocyte Expressed Ligand 2 Protein
Synonyms : HVEM-L Protein, Herpesvirus Entry Mediator-Ligand Protein, TNF Superfamily, Member 14, TNFSF14 Protein, HVEM L Protein, Herpesvirus Entry Mediator Ligand Protein
Synonyms : TL1 Ligand, TL1A Ligand, VEGI (Vascular Endothelial Growth Inhibitor) Protein, Ligand, TL1, Ligand, TL1A
Synonyms : TRAF Proteins, TRAF and TNF Receptor-Associated Protein, TRAF and TNF Receptor-Associated Proteins, TRAF-Interacting Protein, TRAF-Interacting Proteins, TRIP Protein, TNF, TTRAP Proteins, Receptor-Associated Factors, TNF, TNF Receptor Associated Factors
| tumor necrosis factor |
a proinflammatory cytokine that is produced by white blood cells (monocytes and macrophages); has an antineoplastic effect but causes inflammation (as in rheumatoid arthritis)
Ãâó: wordnet.princeton.edu/perl/webwn
|
|---|---|
| tumor necrosis factor |
A type of biological response modifier (a substance that can improve the body's natural response to disease). Three types of tumor necrosis factor have been identified: alpha, beta, and gamma. Tumor necrosis factor seems to play a role in the breakdown of cancer cells.
Ãâó: www.stjude.org/glossary
|
| tumor necrosis factor |
A cytokine produced by many cell types that causes cytolysis of tumor cells, and mediates the expression of genes involved in the defense against disease.
Ãâó: www.genpromag.com/Glossary~LETTER~T.html
|
| tumor necrosis factor |
A cytokine, produced by macrophages, which helps activate T cells. It may also stimulate HIV activity. TNF levels are very high in persons with HIV, and the molecule is suspected to play a part in HIV-related wasting, neuropathy, and dementia. TNF triggers a biochemical pathway that leads to the programmed form of cell suicide known as apoptosis. It also activates a key molecule that can block this very pathway, and so set up a delicate life-death balance within the cell.
Ãâó: www.amfar.org/cgi-bin/iowa/bridge.html
|
| tumor necrosis factor |
TOOM-er nek-RO-sis FAC-tor (TNF) An immune system biochemical with varied functions in cancer, infection, and inflammation. 797
Ãâó: www.mhhe.com/biosci/genbio/life/glossaryt.mhtml
|
| tumor necrosis factor | a proinflammatory cytokine that is produced by white blood cells (monocytes and macrophages) |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|